By Gabriel Paijo 
The landscape of oncology is witnessing a potential paradigm shift in the treatment of triple-negative breast cancer (TNBC), one of the most recalcitrant and aggressive forms of malignancy. Researchers at the Medical University of South Carolina (MUSC) Hollings Cancer Center have announced the development of an experimental humanized monoclonal antibody designed to dismantle the multifaceted survival mechanisms of TNBC. This novel therapeutic approach, detailed in a study recently published in the journal Breast Cancer Research, targets a specific protein known as secreted frizzled-related protein 2 (SFRP2). By inhibiting this protein, the research team demonstrated an ability to not only suppress primary tumor growth and prevent metastatic spread to the lungs but also to effectively "re-engineer" the immune system to recognize and attack cancer cells that had previously evaded detection or developed resistance to conventional chemotherapy.
Triple-negative breast cancer remains a significant clinical challenge because it lacks the three primary receptors—estrogen, progesterone, and the HER2 protein—that serve as targets for many modern breast cancer therapies. This absence of "druggable" targets means that patients are often limited to systemic chemotherapy, which, while initially effective for some, frequently leads to the emergence of highly resistant cell populations. TNBC is characterized by its rapid progression, high rate of early metastasis, and a tendency to recur within the first three to five years following diagnosis. The MUSC Hollings Cancer Center’s discovery of a pathway to bypass these limitations represents a vital step toward providing a precision medicine alternative for a patient population that currently faces a disproportionately high mortality rate.
The SFRP2 Protein: A Multi-Functional Driver of Malignancy
The cornerstone of this research is the identification of SFRP2 as a master regulator within the tumor microenvironment. Unlike many proteins that serve a singular function, SFRP2 has been found to facilitate cancer progression through three distinct avenues: the promotion of angiogenesis, the inhibition of apoptosis (programmed cell death), and the induction of immune exhaustion. By secreting this protein, TNBC tumors are essentially able to build their own infrastructure, ensuring a steady supply of nutrients through new blood vessels while simultaneously creating a "shield" that prevents the body’s natural immune defenses from intervening.
The preclinical study, led by Nancy Klauber-DeMore, M.D., a breast surgical oncologist and co-leader of the Developmental Cancer Therapeutics Research Program at Hollings, builds upon nearly two decades of investigation. Dr. Klauber-DeMore’s lab first identified the overexpression of SFRP2 in breast cancer in 2008. Since then, her team has worked to map the precise molecular pathways through which the protein operates. The latest findings confirm that SFRP2 is not only present in the cancer cells themselves but is also heavily expressed in the surrounding stroma and immune cells, creating a pervasive environment that supports tumor longevity.
Chronology of Discovery and Experimental Methodology
The development of the SFRP2 antibody is the culmination of a multidisciplinary effort involving MUSC’s departments of Surgery, Biochemistry and Molecular Biology, and Pathology and Laboratory Medicine. The research timeline reflects a systematic transition from basic bench science to sophisticated preclinical modeling.
- Initial Identification (2008): Dr. Klauber-DeMore identifies SFRP2 as a key biomarker in breast cancer tissue, noting its absence in healthy breast tissue.
- Mechanism Mapping (2009–2018): Researchers determine that SFRP2 stimulates the Wnt signaling pathway, which is critical for the formation of tumor-associated blood vessels and the survival of cancer cells under stress.
- Antibody Engineering (2019–2022): The team develops a humanized monoclonal antibody. This process involves engineering the antibody to ensure it can be safely administered to humans without being rejected by the immune system, while maintaining high specificity for the SFRP2 protein.
- Preclinical Testing (2023–2024): Led by surgical residents Lillian Hsu, M.D., and Julie Siegel, M.D., the team tests the antibody in various TNBC models, including human tumor samples and mouse models designed to mimic advanced, metastatic disease.
The study’s methodology involved analyzing human TNBC samples to verify the presence of SFRP2 across different cellular components of the tumor. This was followed by in vivo testing, where the antibody was administered to mice with established tumors. Researchers utilized advanced imaging and molecular profiling to track the antibody’s localization and its impact on both the tumor and the systemic immune response.
Reprogramming the Immune Microenvironment
Perhaps the most significant finding of the study is the antibody’s ability to manipulate tumor-associated macrophages (TAMs). Macrophages are white blood cells that generally exist in two states: the M1 phenotype, which is "pro-inflammatory" and attacks cancer cells, and the M2 phenotype, which is "anti-inflammatory" and inadvertently protects the tumor while promoting tissue repair. In aggressive cancers like TNBC, the tumor microenvironment often "re-educates" macrophages to adopt the M2 state, effectively turning the body’s defenders into accomplices for the cancer.
Dr. Klauber-DeMore’s team discovered that SFRP2 is expressed on these tumor-associated macrophages—a first in the field of oncology research. Treatment with the SFRP2 antibody was found to trigger the release of interferon-gamma, a potent immune-signaling molecule. This release pushed the macrophages from the suppressive M2 state back into the cancer-fighting M1 state.
Crucially, this "re-programming" occurred without the systemic toxicity often associated with direct interferon-gamma therapy. By targeting the protein locally within the tumor environment, the researchers achieved a targeted immune activation. This activation extended to T-cells, which are the primary "soldiers" of the immune system. In many TNBC cases, T-cells become "exhausted" and lose their ability to kill cancer cells. The SFRP2 antibody was shown to restore T-cell activity, suggesting that this therapy could potentially work in tandem with existing immunotherapies, such as checkpoint inhibitors, to improve overall response rates.
Addressing Chemotherapy Resistance and Metastatic Spread
One of the most daunting hurdles in treating TNBC is doxorubicin resistance. Doxorubicin is a foundational chemotherapy drug, but TNBC tumors frequently adapt to its presence, leading to treatment failure. The MUSC Hollings team specifically tested the SFRP2 antibody against cancer cells that had been engineered to resist doxorubicin. The results were striking: the antibody remained highly effective at inducing cell death in these resistant populations. This suggests that the SFRP2 pathway is distinct from the pathways used to evade traditional chemotherapy, providing a new "backdoor" to destroy stubborn tumors.
In addition to primary tumor control, the antibody demonstrated a robust capacity to inhibit metastasis. In advanced models of TNBC, mice treated with the antibody showed a significant reduction in lung tumors compared to control groups. Because lung metastasis is a leading cause of death in breast cancer patients, the ability to restrict the cancer’s spread to the respiratory system is of paramount clinical importance.
The precision of the antibody was also validated through biodistribution studies. Researchers found that the antibody accumulated specifically in the tumor tissue, with negligible uptake in healthy organs like the heart, liver, or kidneys. This high degree of selectivity is a major advantage over traditional chemotherapy, which circulates throughout the body and causes the debilitating side effects—such as hair loss, nausea, and immune suppression—that many patients struggle to endure.
Regulatory Status and Future Clinical Outlook
The promising results from the Hollings Cancer Center have already led to significant regulatory and commercial milestones. The antibody technology has been licensed to Innova Therapeutics, a biotechnology firm co-founded by Dr. Klauber-DeMore. The company is currently focused on securing the necessary funding to transition the research into a Phase I clinical trial, which would mark the first time the therapy is tested in human subjects.
Recognizing the potential impact of this research, the U.S. Food and Drug Administration (FDA) has already granted the therapy Rare Pediatric Disease and Orphan Disease designations for its potential use in treating osteosarcoma. Osteosarcoma is a bone cancer that, like TNBC, is highly dependent on SFRP2 for growth and metastasis. While these designations do not yet allow for general clinical use, they provide significant incentives and an accelerated pathway for development, highlighting the FDA’s interest in the SFRP2-targeting mechanism.
Analysis of Implications for the Oncology Field
The implications of this study extend beyond the treatment of TNBC. By focusing on the tumor microenvironment rather than just the cancer cells themselves, the MUSC Hollings researchers are participating in a broader trend toward "ecological" oncology. This approach recognizes that a tumor is not an isolated mass of cells but a complex ecosystem that relies on its surroundings to survive.
From a clinical perspective, if the SFRP2 antibody proves successful in human trials, it could serve as a vital component of a multi-modality treatment regimen. It could be used as a neoadjuvant therapy to shrink tumors before surgery, as a maintenance therapy to prevent recurrence in high-risk patients, or in combination with chemotherapy to prevent the development of drug resistance. Furthermore, the discovery of SFRP2 on macrophages opens new avenues for research into other "cold" tumors—cancers that typically do not respond to immunotherapy.
The research also underscores the importance of long-term investment in basic science. The twenty-year journey from the initial identification of SFRP2 to the development of a humanized antibody demonstrates that breakthrough medical innovations often require decades of persistent, specialized inquiry. As the team at MUSC Hollings Cancer Center moves toward clinical trials, the oncology community remains cautiously optimistic that this "triple threat" antibody may finally provide a formidable weapon against one of the most devastating forms of breast cancer.